Physician & Investor Briefing · Imaging & Physiology

The Burnout Behind the Console: Cardiovascular Imaging's Workforce Crisis

New survey data puts a number on a problem imagers have felt for years, and the fix looks structural, not spiritual.

Cardiology Practice & Markets Reading time: ~6 minutes

Nearly three in five cardiovascular imaging physicians now describe themselves as burned out, according to new survey data presented at the 2026 Society of Cardiovascular Computed Tomography meeting.

That figure lands in a field that has been treated as a niche corner of cardiology and radiology, even as its clinical footprint has exploded.

The survey's authors argue that burnout here is not the generic, well-documented phenomenon seen across medicine, but a distinct symptom of a supply-demand mismatch that is about to get worse.

For a physician-investor audience, that distinction matters, because the same forces driving physicians out of the reading room are also reshaping which companies profit from the imaging pipeline.

A Niche Field, a Loud Signal

The survey drew responses from 248 physicians, two-thirds of whom identified as cardiologists and one-third as radiologists, with 66% in mid-career between ages 36 and 55.

Fifty-eight percent reported feelings of burnout, and more than two-thirds said they routinely work outside scheduled hours, a pattern researchers called "pajama time."

Thirty-seven percent reported working after hours every single day.

Physicians reporting burnout were more than twice as likely to say they were considering leaving practice compared with their non-burned-out peers (21% versus 9%).

Clinical workload and workflow inefficiency outweigh administrative burden as the leading drivers, a pattern distinct from prior burnout literature in general cardiology.

Not the Usual Suspects

Notably, the survey found no statistically significant difference in burnout rates by sex or age group, which diverges from patterns reported in broader physician burnout literature.

Respondents reporting burnout were also significantly less likely to say they had adequate institutional support.

The society's outgoing president framed this as evidence that burnout in cardiac imaging is not a personal deficiency but a structural feature of how imaging work is currently organized.

The Supply-Demand Undertow

The immediate trigger for burnout is workload, but the underlying pressure is a worsening imbalance between imaging demand and available imager capacity.

Workforce modeling cited by the American College of Radiology points to a shortfall of nearly 20,000 radiology and related specialists by 2036.

On the cardiology side, separate projections reported by the American College of Cardiology estimate that the ratio of cardiovascular patients to cardiologists will rise from roughly 1,087-to-1 in 2025 to 1,700-to-1 by 2035.

That same analysis found that counties with a cardiologist density of about 13 per 100,000 residents had the lowest cardiovascular mortality, yet only a small fraction of U.S. counties currently meet that threshold.

A near-56% increase in patient load per cardiologist over a decade is the macro backdrop against which imaging burnout is unfolding.

Why a Meditation App Won't Fix It

A recurring theme at the meeting was skepticism toward wellness interventions aimed at individual coping rather than workflow redesign.

Physicians in the audience pointed to duplicated work, such as both a cardiologist and a radiologist independently reading the same cardiac CT angiogram, without billing structures that reflect either party's effort.

Junior physicians, whose productivity is often measured in RVUs, are described as disproportionately affected by this kind of uncompensated duplicate work.

The consistent ask from frontline imagers was fewer logins, fewer redundant systems, and workflow tools that reduce clicks rather than add wellness programming on top of an unchanged workload.

Where Technology and Capital Intersect

The gap between imaging demand and imager supply is precisely the opening that health-system administrators and investors are pointing toward workflow automation and AI-assisted reporting to fill.

GE HealthCare Technologies NASDAQ: GEHC, the imaging-equipment spinout from General Electric, has been expanding digital and AI-enabled imaging platforms aimed at consolidating fragmented reading workflows.

RadNet NASDAQ: RDNT, an outpatient diagnostic imaging operator, has built out a dedicated artificial-intelligence segment intended to help radiologists handle rising volume without proportional headcount growth.

Both companies illustrate the same physician-investor tension at the heart of this story: tools marketed as burnout relief are also, from a balance-sheet perspective, productivity and margin levers.

Whether a given workflow tool actually reduces a physician's daily click count, versus simply enabling a health system to expect more volume from the same imager, is an empirical question practices should ask before adopting any platform.

Table 1. Publicly Traded Companies With Exposure to Cardiovascular Imaging Workflow and Workforce Capacity

Company	Ticker	Relevant Exposure	Analyst Consensus	Approx. Price Target
GE HealthCare Technologies	GEHC	CT/MR imaging hardware, AI-enabled digital workflow (Allia, MIM Anyware)	Buy	~$79–82
RadNet	RDNT	Outpatient imaging centers; dedicated AI/Digital Health segment	Strong Buy	~$80–90

Prices and analyst targets are approximate and sourced from StockAnalysis.com as of late July 2026; markets move daily and these figures should be independently verified before any investment decision.

Table 2. Burnout Drivers vs. Systems-Level Interventions Discussed at SCCT 2026

Reported Driver	% Citing Driver	Systems-Level Response Discussed
Clinical workload	60%	Panel/protocol standardization; shared reading pools
Inefficient workflows	52%	Single sign-on, consolidated reading platforms
Administrative burden	42%	Ancillary staff support; reduced duplicate documentation
Leadership/institutional culture	42%	Physician-inclusive governance; RVU/billing reform
Work-life integration	41%	Protected non-clinical time; realistic panel sizing
After-hours work ("pajama time")	35%	Workload caps; after-hours coverage pools

Case Vignette

A 42-year-old interventional cardiologist with a growing structural heart imaging practice notices she is finishing CT and echo reports most nights after her children are asleep.

Her hospital recently added a wellness stipend covering a meditation app subscription, but her reading queue and documentation burden have not changed.

Recognizing "pajama time" as a workflow signal rather than a personal failing, she brings volume and turnaround-time data to her division chief and proposes a shared overnight reading pool with the radiology department.

This case illustrates how the SCCT 2026 survey data can be used at the practice level: as a concrete argument for structural change rather than another individual wellness intervention.

Bottom Line

Burnout among cardiovascular imagers is running at 58%, driven primarily by workload and workflow inefficiency rather than administrative tasks alone, and it tracks a widening gap between imaging demand and specialist supply projected to persist through the mid-2030s.

For clinicians, the actionable lever is reframing burnout as a workforce and systems problem worth raising with leadership, not a personal resilience deficit to be managed with wellness apps.

For physician-investors, the same workforce gap is the demand driver behind imaging-equipment and AI-workflow companies, though it is worth distinguishing tools that genuinely reduce physician workload from those that primarily enable higher throughput expectations.

Physician education disclaimer: This article summarizes published survey data and professional society commentary for educational purposes and does not constitute clinical, employment, or wellness guidance for any individual physician or practice.

Financial disclaimer: This article is for general informational purposes only and does not constitute investment advice or a recommendation to buy or sell any security; stock prices, ratings, and price targets are time-sensitive and subject to change without notice. Consult a licensed financial advisor before making investment decisions.

Watch

• Physician Burnout: It's Not a Resiliency Deficit — panel discussion on systems-level causes of physician burnout.
• American College of Cardiology — Official Video Channel — ongoing coverage of cardiovascular workforce and well-being topics.

References

1. Burnout Uniquely Rampant Among Cardiac Imagers. TCTMD, July 20, 2026.
2. Burnout Fueling Workforce Woes. ACR Bulletin, American College of Radiology.
3. A Workforce in Crisis: Navigating the Cardiovascular Clinician Shortage. Cardiology Magazine, American College of Cardiology.
4. GE HealthCare Technologies (GEHC) Stock Overview. StockAnalysis.com.
5. RadNet (RDNT) Stock Overview. StockAnalysis.com.

Prepared for physician-investor education. Not medical or financial advice.

Imaging & Physiology · Cath Lab Safety · Physician-Investor Briefing

One Scan, Three Answers: How CT Is Redrawing Coronary Risk Assessment — and Why the Cath Lab Itself Needs Protecting

Anatomy, physiology, and inflammatory biology are converging inside a single non-invasive scan, while a new multisociety consensus argues the people performing these procedures deserve the same modernization.

July 23, 2026 · 9-minute read · For cardiology, radiology, and physician-investor audiences

Coronary computed tomography angiography has quietly graduated from a gatekeeper test to a full risk-stratification platform.

A joint ACC/AHA chest pain guideline already assigns CCTA its strongest possible recommendation for evaluating both acute and stable symptoms in patients without known disease.

The Society of Cardiovascular Computed Tomography has called that shift decades in the making, since roughly 15 to 20 million U.S. patients fall into the intermediate-to-high-risk category the guideline targets.

New data presented this month push the technology further still, showing that a single CT acquisition can now flag vascular inflammation on top of calcium and plaque, even when no contrast is given.

Meanwhile, a separate multisociety document is asking a parallel question: if imaging technology has evolved this quickly, why hasn't operator radiation protection kept pace?

This briefing walks through both threads and the practice, and portfolio, implications for each.

Figure 1. A single CCTA or non-contrast gated CT acquisition can now inform anatomic, physiologic, and inflammatory risk assessment.

Why CCTA Earned Its "Game-Changer" Label

The 2021 AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR chest pain guideline gave CCTA a Class 1, Level A recommendation, the strongest rating a diagnostic test can receive.

That rating reflected more than a decade of trial evidence showing CCTA works as a non-invasive, cost-effective front-line test.

The test's real advantage is that it no longer answers a single question.

A single acquisition can characterize anatomy through calcium scoring and plaque volume, physiology through CT-derived fractional flow reserve, and now biology through quantitative inflammation markers.

CAD-RADS 2.0 formalizes part of this shift by adding plaque burden modifiers, so a patient with only mild stenosis but heavy plaque burden can still be flagged for aggressive lipid-lowering therapy.

That distinction matters clinically because a normal CCTA carries a very high negative predictive value, yet a meaningful share of future infarctions arise from non-obstructive plaque that a stress test alone would miss.

Quantifying Inflammation: The Next Layer on Top of Calcium

New data presented at the 2026 Society of Cardiovascular Computed Tomography meeting extend this idea directly into the inflammation space.

Investigators used the ORFAN study cohort, drawing on 19,159 patients from nine United Kingdom centers followed for a median of 6.8 years.

The tool in question, a CT-derived fat attenuation index (FAI) score, measures inflammatory changes in the fat surrounding the coronary arteries.

Across the full cohort, the FAI score significantly improved risk stratification beyond calcium scoring and plaque volume alone.

The most striking finding was that this benefit was strongest in patients with a zero calcium score, a group traditionally reassured and discharged from further workup.

In that zero-calcium subgroup, each standard-deviation increase in FAI score corresponded to roughly a 50% higher hazard of cardiovascular mortality.

Critically, the prognostic signal held up whether the scan used contrast or was a plain, non-contrast gated CT, which broadens the pool of patients who could benefit since most calcium-score-only scans are acquired without contrast.

A companion poster from the ongoing FORTIFY trial reinforced the point in a different population: post-MI patients already on optimized guideline-directed therapy.

Despite excellent medical management, roughly six in ten of these well-treated patients still showed elevated coronary inflammation on CT.

That trial is testing an investigational monoclonal antibody targeting oxidized LDL in patients with this kind of persistent inflammation, so a positive readout could eventually give clinicians a therapy to pair with the diagnostic signal.

The technology behind the FAI score is currently supported through research funding and a pilot program, and remains under regulatory review in the United States, so routine clinical availability and reimbursement are not yet established.

One clinician involved in the research also noted a future use case worth watching: serial FAI scanning to track whether anti-inflammatory or lipid-lowering therapy is actually working, something a rising calcium score cannot tell you since calcification itself increases with statin therapy.

Figure 2. Coronary inflammation added the greatest incremental prognostic value in patients otherwise classified as low-risk by calcium score, based on ORFAN cohort data.

Case Vignette

A 54-year-old with a strong family history of premature coronary disease and an LDL cholesterol in the 190s undergoes a coronary calcium scan that returns a score of zero.

Under a purely calcium-based framework, this result might be reassuring enough to defer statin intensification.

If the same non-contrast dataset were run through an inflammation-quantification algorithm and returned an elevated fat attenuation index, the clinical conversation would shift meaningfully toward earlier, more aggressive lipid-lowering therapy despite the "clean" calcium result.

This scenario illustrates exactly the population the newest ORFAN analysis identifies as gaining the most from inflammation quantification: patients a calcium score alone would under-classify.

Cath Lab Radiation Safety: A Parallel Modernization Push

While imaging is getting smarter, a separate multisociety effort is asking whether protecting the people who perform these procedures has kept pace.

A new consensus statement led by the Society for Cardiovascular Angiography and Interventions, alongside echocardiography, rhythm, interventional radiology, and vascular surgery societies, argues that traditional lead-apron-based ALARA practice is now outdated.

Enhanced radiation protection devices (ERPDs), including mobile and ceiling-mounted barrier systems, radiation-attenuating drapes, and robotic or remote-controlled systems, have been shown to cut operator and staff radiation exposure by as much as 99% compared with standard lead-apron protection.

The document is notable for its tone: rather than reminding operators to wear thicker lead, it calls on hospitals, manufacturers, and regulators to share responsibility for adopting these systems.

Authors specifically point to fluoroscopy equipment manufacturers as bearing primary responsibility for building radiation-minimizing features directly into their systems.

They also emphasize that real-time dosimetry should accompany every ERPD, since it gives operators immediate feedback during the learning curve of adopting lower-lead or lead-free workflows.

State-level variability complicates adoption, since some states allow reduced or no lead apparel with certain systems while others do not yet formally recognize these newer barrier technologies.

The consensus authors call for a national certification program for fluoroscopy lab personnel, a standardized dose-monitoring platform, and a national occupational exposure registry to bring consistency to this landscape.

The stakes are not abstract: musculoskeletal injury from wearing heavy lead for decades, alongside radiation-related health risks, has long been described as an accepted occupational hazard of interventional practice.

Representative ERPD Categories Discussed in the Consensus Statement

Protection Category	Primary Beneficiary	Reported Exposure Reduction
Ceiling/table-mounted transparent barrier systems	Operator	≥90%
Panel-based transparent barrier systems	Operator plus assistant	≥90%
Body-worn robotic/suspended shielding	Operator	Up to 99%
Configurable radiation-protection systems	Entire staff	≥90%

Figures reflect ranges reported in the SCAI/ASE/HRS/SIR/SVS expert consensus statement; individual system performance varies by procedure type and room configuration.

The Investor Lens: Imaging Hardware, AI Analytics, and Cath Lab Safety

None of the diagnostic companies behind FAI quantification or coronary AI plaque analysis are publicly traded, so thematic exposure for now runs mainly through the CT hardware and broader device makers that build and sell the scanners and cath lab equipment these tools run on.

Company / Technology	Role	Ticker	Analyst Consensus
GE HealthCare (CT imaging systems)	Cardiac CT hardware, AI-enabled acquisition	NASDAQ: GEHC	Buy
Siemens Healthineers (CT imaging systems)	Cardiac CT hardware, Imaging segment	OTC: SMMNY	Strong Buy
Boston Scientific (interventional cardiology)	Cath lab devices; broader interventional exposure	NYSE: BSX	Strong Buy
Caristo Diagnostics (CaRi-Heart / FAI technology)	FAI score analytics	no ticker	—
Abcentra (orticumab, FORTIFY trial)	Investigational anti-inflammatory antibody	no ticker	—
Egg Medical, Rampart IC, StemRad, Biotronik, Image Diagnostics (ERPD systems)	Enhanced radiation protection devices	private / segment of larger co.	—

Where a company is private, exposure is best framed thematically through the publicly traded imaging and device peers rather than through the company itself.

Regulatory clearance timelines matter here: FAI-based inflammation scoring remains under U.S. review, so the addressable market and reimbursement pathway are not yet defined domestically.

Analyst sentiment on the large-cap imaging names has been volatile this year, with several 2026 price-target revisions on both GEHC and BSX, so position sizing should account for that volatility rather than treat these as pure plays on any single technology theme.

Bottom Line

A single CT acquisition can now deliver anatomic, physiologic, and inflammatory risk data, and the inflammatory layer appears most valuable precisely in patients a calcium score would otherwise reassure.

Separately, a multisociety consensus is pushing cath lab radiation protection from an individual responsibility toward a regulatory and institutional one.

Both threads point toward the same broader trend: modernizing tools that have functionally not changed in decades, whether that tool is a risk calculator or a lead apron.

Financial exposure to date runs through CT hardware and device incumbents rather than the still-private diagnostic-analytics innovators themselves.

Physician education disclaimer: This article is intended for physician education and does not constitute individualized clinical guidance; treatment decisions should be based on current guidelines and individual patient assessment.

Financial disclaimer: This content is for informational purposes only and does not constitute investment advice or a recommendation to buy or sell any security; stock prices, analyst ratings, and price targets are time-sensitive and subject to change. Consult a licensed financial advisor before making investment decisions.

---

Watch

• TCTMD YouTube channel — conference coverage and topical discussions on coronary imaging and cath lab practice

References

1. 2021 AHA/ACC Chest Pain Guideline Perspectives. American College of Cardiology.
2. CCTA Receives Multiple Class 1, Level A Recommendations in 2021 New Chest Pain Guideline. Society of Cardiovascular Computed Tomography.
3. Quantifying Inflammation Can Add to CV Risk Prediction Even in No-Contrast Scans. TCTMD, July 2026.
4. FORTIFY Trial Record. ClinicalTrials.gov.
5. SCAI Calls for 'Regulation-Mandated' Enhanced Radiation Safety. TCTMD, July 2026.

Structural Heart · Interventional Cardiology

AnchorMan vs. Watchman: A Challenger Device Clears Its First Head-to-Head Test in Left Atrial Appendage Closure

Twelve-month data from a randomized China-based trial suggest a new occluder can match the market leader on safety and efficacy, and may seal better.

A novel left atrial appendage closure device out of China has posted one-year outcomes that look essentially indistinguishable from the market-leading occluder.

The device, called AnchorMan, comes from MicroPort CardioFlow, a Shanghai-based structural heart company.

Its comparator was the first-generation Watchman 2.5 device, the implant that opened the LAAC category in the United States back in 2015.

For a physician audience managing stroke-risk conversations in nonvalvular atrial fibrillation every week, this trial is a useful checkpoint on where device competition in this space is heading.

Why This Trial Matters

Roughly nine in ten strokes tied to nonvalvular AFib originate from thrombus forming in the left atrial appendage, which is the rationale behind mechanically excluding it from circulation.

The original Watchman device was approved to reduce thromboembolic risk in patients with an appropriate reason to avoid chronic anticoagulation, and it has since become the dominant device worldwide.

Because anatomic variability in the appendage remains a real procedural challenge, newer occluders keep entering development to improve sealing and ease of deployment.

The trial behind this analysis, called SAFE-PROTECT, randomized patients head-to-head between AnchorMan and Watchman 2.5 rather than comparing either device to a historical benchmark.

How the Devices Differ

AnchorMan's distal end is rounded, a design choice intended to increase surface contact with appendage tissue while reducing the chance of intraoperative or delayed perforation.

Twelve so-called "3D folding" units form what the manufacturer describes as a semiclosed cage, a structural approach meant to combine features of both open and closed occluder designs.

This cage construction is also designed to let operators implant the device at a shallower depth within the appendage than some competing occluders require.

Both devices cleared the noninferiority bar for clinical success; the residual-leak gap favored AnchorMan's sealing performance.

What the Trial Found

A total of 216 patients with nonvalvular AFib and elevated stroke risk were randomized between the two occluders.

The primary endpoint, 12-month clinical success (freedom from stroke, systemic embolism, and cardiovascular or unexplained death), landed at 98.1% in both arms, meeting the prespecified noninferiority margin.

Echocardiography-confirmed appendage occlusion at 12 months was essentially identical between groups as well.

Rates of all-cause death, major bleeding, and device-related complications did not differ meaningfully between the two occluders.

The one signal that separated the devices was peridevice leak greater than 3mm, which occurred less often with AnchorMan, a finding the investigators attributed to its distinct sealing geometry.

A follow-up randomized study comparing AnchorMan against the newer Watchman FLX and FLX Pro platforms is already being planned.

Table 1. SAFE-PROTECT Trial at a Glance

Parameter	Detail
Design	Multicenter, randomized, head-to-head
Population	Nonvalvular AFib, elevated ischemic stroke risk, poor candidates for long-term anticoagulation
Comparator device	Watchman 2.5 (Boston Scientific)
Investigational device	AnchorMan (MicroPort CardioFlow)
Primary endpoint	12-month clinical success, 98.1% vs. 98.1%
Funding	MicroPort CardioFlow-sponsored; sponsor reported no role in data analysis or the decision to publish

Table 2. Watchman Platform Timeline vs. AnchorMan Regulatory Status

Device	Milestone	Regulator / Year
Watchman (original)	First LAAC device cleared for stroke risk reduction	FDA, 2015
Watchman FLX	Fully rounded, recapturable design	FDA, July 2020
Watchman FLX Pro	Thromboresistant coating, larger size option	FDA, September 2023
AnchorMan	Market approval, China only; not yet FDA-reviewed	NMPA, January 2024

The Investor Overlay

For a physician-investor readership, this trial is as much a competitive-landscape story as a clinical one.

NYSE: BSX — Boston Scientific HKG: 2160 — MicroPort CardioFlow

Table 3. Company Snapshot

Company	Ticker	Analyst Consensus	12-Month Price Target
Boston Scientific	NYSE: BSX	Strong Buy (31 analysts)	$77.10, roughly 69% above the recent price
MicroPort CardioFlow	HKG: 2160	Strong Buy (2 analysts, limited coverage)	HK$7.06, a wide-range estimate given thin analyst following

Boston Scientific's Watchman franchise remains the dominant revenue driver in the LAAC category, and the company has already layered two newer-generation devices, FLX and FLX Pro, on top of the original 2.5 platform used in this trial.

MicroPort CardioFlow is a much smaller, thinly covered name whose Hong Kong-listed shares carry considerably more volatility and analyst uncertainty than BSX.

AnchorMan's commercial footprint today is limited to China and a handful of early international cases in Latin America and Europe, and it has not yet been reviewed by the FDA.

Any US market entry would likely require AnchorMan to be tested against the newer Watchman FLX and FLX Pro devices rather than the older 2.5 platform used in SAFE-PROTECT, which is exactly the next study the investigators say is planned.

The Medical Alternative: Anticoagulation

Long-term anticoagulation remains the non-device comparator physicians weigh against LAAC in most stroke-prevention conversations.

Table 4. Cost Comparison: LAAC vs. a Representative DOAC

Option	Brand / Generic	Approx. Monthly Cost	Company
LAAC device	Watchman 2.5 / FLX / FLX Pro	One-time procedural cost, not a recurring drug expense	Boston Scientific (NYSE: BSX)
LAAC device	AnchorMan	One-time procedural cost; not commercially available in the US	MicroPort CardioFlow (HKG: 2160)
Oral anticoagulant	Brand Eliquis (apixaban)	Roughly $350–$600, before manufacturer copay assistance	Bristol Myers Squibb (NYSE: BMY) / Pfizer (NYSE: PFE)
Oral anticoagulant	Generic apixaban	Roughly $30–$80 with a discount card	Multiple generic manufacturers

Drug prices shown are point-in-time GoodRx figures and vary by pharmacy, region, and insurance coverage.

Case Vignette

A 74-year-old woman with paroxysmal nonvalvular AFib, a CHA₂DS₂-VASc score of 5, and a gastrointestinal bleed six months ago on apixaban is referred for stroke-prevention options.

She has already failed a trial of dose-reduced anticoagulation with recurrent minor bleeding, and her HAS-BLED score is 4.

Transesophageal echocardiography shows a chicken-wing morphology appendage without thrombus, making her anatomically suitable for closure.

She undergoes Watchman FLX implantation uneventfully and is transitioned to a short antiplatelet regimen per current protocols.

This is exactly the patient population in which a competitor device with a lower peridevice-leak signal, like AnchorMan, could eventually matter clinically once (and if) it reaches FDA review.

Bottom Line

AnchorMan met noninferiority against Watchman 2.5 on the primary safety and efficacy endpoint at 12 months, with a possible sealing advantage that will need confirmation.

The device is not yet available in the United States, and its next comparative trial will need to clear the higher bar set by Watchman FLX and FLX Pro rather than the first-generation platform.

For US-based physicians, this is a name worth tracking rather than a near-term change to practice.

---

Watch

Watchman FLX Product Animation (Boston Scientific)

References

1. SAFE-PROTECT 12-month randomized trial results, EuroIntervention, July 2026.
2. TCTMD coverage of the initial SAFE-PROTECT presentation, EuroPCR 2023.
3. MicroPort primary endpoint announcement, May 2023.
4. ACC update on Watchman FLX Pro approval, September 2023.
5. TCTMD coverage of original Watchman FLX approval, July 2020.
6. MicroPort update on AnchorMan's NMPA approval and China rollout, September 2024.

Physician education disclaimer: This article is intended for healthcare professional education and does not constitute individualized clinical guidance; device selection should follow current professional society recommendations and shared decision-making with each patient.

Financial disclaimer: Stock tickers, analyst ratings, price targets, and drug pricing in this article are for informational purposes only, reflect a single point in time, and are not investment advice; consult a licensed financial advisor before making investment decisions.

Want this reformatted as a short YouTube script, a one-paragraph social summary, or a patient-facing handout on LAAC options? Just ask.

AI in the Cath Lab · Practice & Investment

AI Voice Agents in the Cath Lab: What the Sofiya Pilot Means for Practice

A 90-day pilot of an agentic voice assistant handling pre-procedural calls offers a data point on where administrative AI is heading in interventional cardiology — and which public companies sit near the trend.

A high-volume academic cath lab has spent the past year testing whether a voice-based AI assistant can safely take over one of the most repetitive tasks in pre-procedural care.

The assistant, an agentic conversational system built specifically for the workflow, calls patients the day before catheterization to review logistics, confirm allergies and medications, and answer routine questions.

Two sequential 90-day phases at the Mount Sinai Fuster Heart Hospital cath lab generated the largest published experience with this kind of tool in interventional cardiology to date.

For a specialty facing a worsening nursing shortage, the results are worth a close read.

Why This Matters Now

Preprocedural calls are clinically essential but highly repetitive, covering arrival time, fasting instructions, transportation, and a structured allergy and medication review.

In a lab performing more than 16,000 procedures a year, that workload consumes several full-time nursing hours every single day.

Workforce shortages projected to worsen through 2030 have pushed health systems to look for ways to protect nurses' time for direct, bedside clinical work.

The pilot's central question was whether a large language model-based voice agent could take on this task without compromising safety or the patient experience.

What the Pilot Found

Across two 90-day phases, 1,431 patients received 1,606 calls, and the overall successful-completion rate rose from 86.4% in phase one to 87.9% in phase two.

More than a third of all calls were handled entirely by the AI agent with no nurse involvement at any point.

Roughly another third triggered a brief, protocol-defined nurse callback, and about 12% were escalated to a full human conversation.

Investigators estimated the assistant saved an average of 11 minutes per call, equivalent to more than 37 twelve-hour nursing shifts over a year in this single lab.

Patient satisfaction was high in both phases, and only a small minority of patients declined to speak with the AI system at all.

Six calls were derailed by an AI hallucination — the system generating inaccurate information — out of more than 1,600 attempts, and every transcript was reviewed by a nurse before anything reached the chart.

Metric	Phase 1 (n=806 calls)	Phase 2 (n=800 calls)
Successfully completed calls	86.4%	87.9%
Fully automated, no nurse contact	36.6%	42.6%
Brief protocol-driven nurse callback	37.6%	33.5%
Escalated to full human call	12.2%	11.8%
Patient declined AI call	4.3%	2.8%
Postprocedural satisfaction	94.7%	98.1%

Fig. 1. Disposition of pre-procedural calls handled by the AI voice assistant, by pilot phase.

Fig. 2. Illustrative trend in patient satisfaction across the pilot, alongside the estimated annualized nursing-time offset.

Case Vignette

A 71-year-old woman with stable angina is scheduled for diagnostic catheterization the next morning.

The evening before, an AI voice agent calls to confirm her arrival time, review same-day fasting rules, and ask about allergies and current medications.

She mentions she takes a direct oral anticoagulant that was not listed in her chart, and the system automatically flags the discrepancy for a same-day nurse callback rather than attempting to resolve it itself.

A nurse calls back within the hour, confirms the hold parameters with the proceduralist, and documents the correction — illustrating the intended division of labor between automation and clinical judgment.

Where the Guardrails Are

The design keeps a human in the loop by default: every transcript is reviewed by nursing staff, and any question outside the system's scripted knowledge base triggers a callback rather than an improvised answer.

At the start and end of every call, the assistant identifies itself as a virtual agent and reminds patients that a person is always reachable.

Deployment reportedly required review by roughly a dozen institutional committees, including the health system's first case brought before a dedicated AI governance board.

That governance overhead is worth noting for any practice considering a similar build, since the technical lift is often smaller than the compliance one.

The Investor Angle

The specific platform used in this pilot is an internally customized, vendor-partnered build rather than a standalone public product, so there is no direct ticker to attach to it.

The broader trend it represents, though, touches several publicly traded companies that physician-investors may already be watching.

Company	Ticker	Relevance	Analyst Consensus	12-Mo. Price Target
Sofiya voice-agent platform	no ticker (private)	Custom-built, vendor-partnered agentic AI; not a standalone public offering	—	—
Microsoft	NASDAQ: MSFT	Ambient and agentic clinical AI (Dragon Copilot) competes in the same workflow-automation category	Strong Buy	$558.77 (+39.3%)
Tempus AI	NASDAQ: TEM	Pure-play healthcare AI/data company scaling clinical workflow and diagnostics products	Buy	$66.06 (+12.6%)
GE HealthCare	NASDAQ: GEHC	Cath lab imaging and interventional-suite equipment maker layering AI into existing hardware	Buy	$79.33 (+23.1%)

None of these companies were named as the vendor behind this specific pilot, and the table above should be read as thematic exposure to administrative and clinical AI in cardiology, not as a claim about who built Sofiya.

What Might Come Next

Program leaders have described plans to extend similar AI calling to postprocedural follow-up, appointment scheduling, and cardiac rehabilitation referrals.

Expansion into peripheral and structural heart disease scheduling within the same cath lab has also been discussed as a next step.

Nursing representatives have publicly cautioned that every AI-generated summary still needs a clinician's review before it becomes part of the permanent record.

That tension between efficiency gains and continued oversight is likely to define how quickly this category scales across other cath labs.

Bottom Line

A well-governed, human-in-the-loop AI voice agent handled more than a third of pre-procedural cath lab calls with no nurse involvement and freed an estimated 37-plus nursing shifts a year at a single high-volume site.

The technology performed safely within a narrow, scripted scope, but every escalation pathway and every hallucination in this pilot was caught because a nurse was still reviewing the output.

For practices evaluating similar tools, the governance and review infrastructure may matter as much as the underlying model.

Physician education disclaimer: This article is intended for healthcare professional education and does not constitute clinical guidance for any individual patient; treatment and workflow decisions should follow institutional protocols and clinician judgment.

Financial disclaimer: Stock tickers, analyst ratings, and price targets are provided for informational and educational purposes only, reflect data available as of publication, and do not constitute investment advice or a recommendation to buy or sell any security. This is not a substitute for advice from a licensed financial advisor.

Further Viewing

▶ Harnessing Artificial Intelligence at the Mount Sinai Health System
▶ Mount Sinai Department of Artificial Intelligence (AI) and Human Health

References

1. Meet Sofiya, Mount Sinai's latest AI assistant. Becker's Cardiology.
2. Utilizing an AI-assisted virtual agent for pre-procedural patient calling in the cardiac catheterization laboratory. European Heart Journal – Digital Health, 2026.
3. Mount Sinai Launches Cardiac Catheterization Artificial Intelligence Research Lab. Mount Sinai Newsroom.
4. Microsoft Corporation (MSFT) stock overview. StockAnalysis.com.
5. Tempus AI (TEM) stock forecast. StockAnalysis.com.
6. GE HealthCare Technologies (GEHC) stock overview. StockAnalysis.com.

Lipid Management · New Approval

The First Pill for PCSK9: What Enlicitide's Approval Means for Your Lipid Clinic

Cardiology & Investor Brief · July 16, 2026

The FDA has approved enlicitide (Lipfendra) as the first oral PCSK9 inhibitor for adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia (HeFH).

It is manufactured by MerckNYSE: MRK, and is dosed as a once-daily 20-mg tablet.

Every prior PCSK9 inhibitor on the US market has required an injection, so this approval changes the practical calculus for a large share of statin-intolerant and high-risk patients.

Enlicitide is a novel macrocyclic peptide that binds PCSK9 and blocks its interaction with hepatic LDL receptors, the same target as the injectable antibodies but delivered as an orally stable ring-shaped peptide.

Case Vignette

A 54-year-old patient with heterozygous familial hypercholesterolemia has an LDL-C of 168 mg/dL despite maximally tolerated rosuvastatin and ezetimibe.

The patient has declined every injectable option offered over the past two years, citing needle aversion and a demanding travel schedule that makes cold-chain storage impractical.

An oral, room-temperature-stable PCSK9 inhibitor removes both objections in a single conversation.

This is precisely the patient population most likely to benefit from enlicitide's approval.

What the CORALreef Trials Showed

The approval rests on two Phase 3 trials, CORALreef Lipids and CORALreef HeFH.

In CORALreef Lipids, LDL-C fell 57.1% with enlicitide versus a 3.0% rise with placebo at 24 weeks, an adjusted between-group difference of 55.8%.

In CORALreef HeFH, the between-group LDL-C difference was 59.4%, with both results reaching high statistical significance.

Diarrhea and dizziness were numerically more frequent with enlicitide in the HeFH trial, but discontinuation rates for adverse events were similar between arms.

Enlicitide's placebo-adjusted LDL-C lowering is in the same range as established injectable PCSK9 inhibitors; ranges for comparators reflect prior published trial data, not head-to-head comparison.

Trial	Population	LDL-C Change (Enlicitide vs Placebo)	Notable Adverse Events
CORALreef Lipids	Adults with hypercholesterolemia	-57.1% vs +3.0% (Δ 55.8%, P<0.001)	Similar to placebo overall
CORALreef HeFH	Adults with heterozygous FH	Δ 59.4% (P<0.001)	Diarrhea 7% vs 2%; dizziness 9% vs 4%

Where It Fits Among PCSK9 Inhibitors

Enlicitide joins a crowded but still-growing PCSK9 class that includes inclisiran (Leqvio), evolocumab (Repatha), alirocumab (Praluent), and lerodalcibep (Lerochol).

What sets it apart is not efficacy but the route: a tablet rather than a subcutaneous injection or in-office infusion.

An interventional cardiologist commenting to TCTMD framed this as an access issue rather than a potency issue, since needle aversion and cold-chain logistics keep some appropriate patients from ever starting a PCSK9 inhibitor.

That same commentary was clear that oral PCSK9 inhibition adds to the toolbox rather than replacing existing agents.

Enlicitide is the only oral option; injectable agents differ mainly in dosing interval and self- versus in-office administration.

Financial Snapshot: The PCSK9 Competitive Landscape

Cost has historically limited broader PCSK9 uptake, and the TCTMD commentary noted that access will hinge on pricing and payer pathways once enlicitide launches commercially.

List pricing for enlicitide has not yet been published as of this approval, so clinicians should expect formulary and coupon details to follow in the coming weeks.

Agent (Brand)	Company / Ticker	Analyst Consensus & 12-Mo Target	Cash/List Price Reference
Enlicitide (Lipfendra)	MerckNYSE: MRK	Buy · $132.78 target	Not yet published
Evolocumab (Repatha)	AmgenNASDAQ: AMGN	Hold · $345.12 target	GoodRx cash price from ~$239/mo
Alirocumab (Praluent)	RegeneronNASDAQ: REGN / SanofiNASDAQ: SNY	Buy · $833.31 target (REGN)	GoodRx cash price ~$233/mo
Inclisiran (Leqvio)	NovartisNYSE: NVS	Hold · $154.57 target	GoodRx coupon programs vary; list WAC ~$3,250-3,500/dose
Lerodalcibep (Lerochol)	LIB Therapeutics no ticker (private)	Not applicable	Cash-pay launch price $199/month

What's Still Unknown

No cardiovascular outcomes data yet exist for enlicitide, so a reduction in heart attacks and strokes remains inferred rather than proven.

The ongoing CORALreef Outcomes trial has completed enrollment of more than 14,500 participants and should eventually answer that question.

Merck also has an extension study, a pediatric trial in patients ages 6 to 17, and a combination trial pairing enlicitide with rosuvastatin underway.

Until outcomes data mature, enlicitide should be regarded as a highly effective LDL-lowering option with a favorable surrogate-endpoint profile, not yet a confirmed event-reducing therapy.

Bottom Line

Enlicitide is the first oral PCSK9 inhibitor, matching injectable-class LDL-C reductions of roughly 56-59% in two Phase 3 trials.

It expands options for patients who decline or cannot manage injectable therapy, without replacing existing agents.

Cardiovascular outcomes data are still pending from the ongoing CORALreef Outcomes trial.

Pricing, insurance coverage, and formulary placement will determine how quickly it reaches appropriate patients.

Physician education disclaimer: This article is intended for healthcare professional education and does not constitute clinical practice guidance for any individual patient; treatment decisions should follow current guidelines and individualized clinical judgment.

Financial disclaimer: Stock data, analyst ratings, and price targets are for informational purposes only, reflect a single point in time, and do not constitute investment advice; this is not a recommendation to buy or sell any security.

Related Viewing

For a patient-friendly primer on how this drug class works, see PCSK9 Inhibitors Explained, which covers the mechanism and cardiovascular rationale behind PCSK9 inhibition.

For a clinician-oriented walkthrough of when to use this class in practice, see PCSK9 Inhibitors in Practice.

References

1. Merck news release on LIPFENDRA (enlicitide) FDA approval
2. AJMC coverage of the enlicitide approval
3. TCTMD coverage of the CORALreef Lipids trial
4. GoodRx pricing reference for evolocumab (Repatha)
5. GoodRx pricing reference for inclisiran (Leqvio)
6. LIB Therapeutics LEROCHOL US launch announcement

Want this repackaged as a short YouTube script, a social media summary, or a patient-facing pamphlet on oral vs. injectable cholesterol medications? Just ask.